The European Commission has concluded an advance purchase agreement with AstraZeneca Plc for the supply of up to 400 million doses of a Covid-19 vaccine which it is developing with the University of Oxford. Announced on 14 August, the agreement covers the initial purchase of 300 million doses, with an option for an additional 100 million. The price was not disclosed. However in a separate announcement, AstraZeneca said it would supply the vaccine “in an eqitable manner at no profit during the pandemic.”
